Navigation Links
Lilly Receives Complete Response Letter From FDA for Liprotamase for the Treatment of Exocrine Pancreatic Insufficiency
Date:4/15/2011

INDIANAPOLIS, April 15, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) has received a complete response letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for liprotamase, a non-porcine pancreatic enzyme replacement therapy (PERT), under investigation for the treatment of exocrine pancreatic insufficiency (EPI).

The complete response letter communicated the need for Lilly to conduct an additional clinical trial prior to a re-submission.

"Lilly is looking forward to further discussion with the FDA to address the items outlined in the letter and provide the requested information as quickly as possible," said Eiry Roberts, M.D., Vice President, Autoimmune, Bone-Muscle-Joint, Liprotamase Product Development at Lilly.  "We are committed to working with the Agency and the cystic fibrosis community to make this important treatment option available to patients."

People with EPI have very low levels or none of the key digestive enzymes made by the pancreas - lipase, amylase and protease - in their small intestine, resulting in improper digestion and absorption of fat, carbohydrates and proteins, often requiring treatment with PERTs. EPI occurs very frequently in patients with cystic fibrosis (a life-threatening genetic disorder) and in other diseases including chronic pancreatitis and pancreatectomy.

About Liprotamase

Liprotamase is an oral, non-porcine (not made from harvesting the pancreas of pigs), biotechnology-derived, pancreatic enzyme replacement therapy (PERT) developed to treat patients with EPI associated with cystic fibrosis, chronic pancreatitis and pancreatectomy.

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com.

This press release contains forward-looking statements about liprotamase for the treatment of exocrine pancreatic insufficiency (EPI). It reflects Lilly's current beliefs; however, as with any such undertaking, there are substantial risks and uncertainties in the process of drug development and commercialization. There is no guarantee that liprotamase will be approved by the FDA on the anticipated timeline or at all, or that it will be commercially successful. For further discussion of these and other risks and uncertainties, please see Lilly's latest Forms 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. The companies undertake no duty to update forward-looking statements.

P-LLY

(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO)


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Avant Healthcare Marketing Receives 2010 Lilly Global Sustained Supplier Award
2. Lilly Confirms Date and Conference Call for First-Quarter 2011 Financial Results Announcement
3. Two Novel Lilly Molecules Target Genetic Mutations That Can Lead to Cancer
4. Lillys Connecting Hearts Abroad Program Sends Employees on Global Service Assignments
5. Lilly and Avid Receive Complete Response Letter from FDA for Amyvid™ (florbetapir F 18 injection)
6. NAFE Names Lilly to Top 50 Companies for Executive Women
7. Lilly Makes an Irrevocable Offer to Acquire Janssen Animal Health
8. Lilly Announces New Vice President of Oncology Research
9. Lilly CEO Calls for Biopharmaceutical Industry Changes and Policies That Encourage Medical Innovation
10. Lilly Marks Major Milestone for Mirror Portfolio with Agreement by Independent Fund to License First Two Investigational Medicines
11. Lilly Announces Senior Leadership Changes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... N.Y. , Dec. 6, 2016 ... a reason to be hopeful.  A special kind of ... a less anxious life. Photo - ... Robert Buck, the psychotherapist who developed and ... breakthrough approach to overcoming anxiety and worry.  "Anxiety ...
(Date:12/5/2016)... , Dec. 5, 2016  Zimmer Biomet Holdings, ... announced that, pursuant to its previously-announced cash tender ... in the table below (collectively, the "Notes"), approximately ... validly tendered and not validly withdrawn on or ... time, today, December 5, 2016 (the ...
(Date:12/5/2016)... France Glaucoma Surgery Devices Market Outlook to 2022 ... Market Outlook to 2022", provides key market data on ... value, in millions of US dollars, volume (in units) ... Micro Catheters and Glaucoma Drainage Devices. The report ... each of these market segements, and global corporate-level profiles ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... , ... “The Road To Restoration”: an informative and enlightening book for ... week showing of hands. “The Road To Restoration” is the creation of published author, ... the brass ring that you could reach out for, and grab, on the old ...
(Date:12/7/2016)... ... December 07, 2016 , ... The Business ... Summit in Reston, VA on March 21-22, 2017. This premier event features business ... experiences from a cross-section of industries such as financial services, insurance, healthcare, manufacturing, ...
(Date:12/6/2016)... ... December 06, 2016 , ... The International Vaccine ... a vaccine against the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). The collaboration will ... Korea for emergency deployment in the event of a future outbreak. , IVI ...
(Date:12/6/2016)... ... December 06, 2016 , ... i2i Population Health, a ... a vice president of sales. , “Ajdin understands that building a successful sales ... understand what each client needs, and is persistent in building towards a solution ...
(Date:12/6/2016)... Scottsdale, Arizona (PRWEB) , ... December 06, 2016 , ... ... less than fIve days after launch. Almost 200 backers pledged more than $25,000 ... life-changing technology. , Dr. Amy Serin, an Arizona Neuropsychologist and inventor, ...
Breaking Medicine News(10 mins):